Form 4: Corcept Therapeutics Director Daniel N. Swisher Jr. Acquires 30,000 Stock Options

Director Daniel N. Swisher Jr. of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024.

Summary

• On May 17, 2024, Daniel N. Swisher Jr., a director of Corcept Therapeutics, acquired 30,000 stock options.
• The exercise price of these options is $28.09.
• The options vest ratably in equal monthly installments over one year, starting May 17, 2024.
• The expiration date for these options is May 16, 2034.
• Following the transaction, Swisher directly owns 30,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction filing. The acquisition of options by a director is generally viewed as a positive, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and officers.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates